Details of Disease

General Information of Disease (ID: DISFB8P5)

Disease Name	Central nervous system disease
Synonyms	disorder of central nervous system; disease or disorder of central nervous system; disease of the central nervous system; disease of central nervous system; central nervous system disorder; central nervous system disease or disorder; central nervous system disease; central nervous disease; CNS disorder
Disease Class	8A04-8D87: Central nervous system disease
Definition	A disease involving the central nervous system.
Disease Hierarchy	DISWD40R: Disease DISCFBRD: Neurological disorder DISFB8P5: Central nervous system disease
ICD Code	ICD-11 ICD-11: 8A04-8D87 ICD-10 ICD-10: C71 ICD-9 ICD-9: 191 Expand ICD-11 2A00.11; 2A00.00 Expand ICD-10 C71 Expand ICD-9 191
Disease Identifiers	MONDO ID MONDO_0002602 UMLS CUI C4021765 MedGen ID 892343 HPO ID HP:0002011

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 8 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Dacarbazine	DMNPZL4	Approved	Small molecular drug	[1]
Dasatinib	DMJV2EK	Approved	Small molecular drug	[2]
Gadodiamide	DMXPBAR	Approved	Small molecular drug	[3]
Metrizamide	DM7H57T	Approved	Small molecular drug	[3]
protirelin	DMGN5QD	Approved	Small molecular drug	[3]
Taltirelin	DMSL2S5	Approved	Small molecular drug	[4]
Technetium (99m Tc) bicisate	DM0AG2E	Approved	Small molecular drug	[3]
Temozolomide	DMKECZD	Approved	Small molecular drug	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of 8 Drug(s)

This Disease is Treated as An Indication in 9 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Enzastaurin	DM5H0R9	Phase 3	Small molecular drug	[6]
HuCNS-SC	DM1ROIC	Phase 2	NA	[7]
CPH-106	DMNS1KU	Phase 1	NA	[8]
CTD-02	DMU9B37	Phase 1	NA	[9]
P28 cell penetrating peptide	DMA2JQD	Phase 1	NA	[10]
P53 cell pentrating peptide	DMMU2HI	Phase 1	NA	[11]
SA-5845	DM6XZRL	Phase 1	NA	[12]
SPN-809	DMK7OCT	Phase 1	NA	[13]
TRN-148	DMH1OYY	Clinical Trial	NA	[14]
------------------------------------------------------------------------------------


⏷ Show the Full List of 9 Drug(s)

This Disease is Treated as An Indication in 4 Patented Agent(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Phenylsulfonyl derivative 1	DM9NOP3	Patented	Small molecular drug	[15]
Phenylsulfonyl derivative 2	DM63128	Patented	Small molecular drug	[15]
Phenylsulfonyl derivative 3	DME6FLN	Patented	Small molecular drug	[15]
Phenylsulfonyl derivative 4	DM1HYW4	Patented	Small molecular drug	[15]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 2 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
NWP-08	DMLAU1Z	Discontinued in Phase 2	NA	[16]
ReN-1826	DMGY51F	Terminated	NA	[19]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 2 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Glial cell line-derived neurotrophic factor protein	DM3AB4O	Preclinical	NA	[17]
PMX205	DMMXR3L	Preclinical	Small molecular drug	[18]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 31 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ACP-106	DMBVHLT	Investigative	NA	[20]
ADX-63365	DMA74PO	Investigative	Small molecular drug	[21]
AL-209	DM7XHDC	Investigative	NA	[22]
AL-309	DM69X2Z	Investigative	NA	[22]
AL-408	DM7K360	Investigative	NA	[23]
AL-508	DM12R4X	Investigative	NA	[13]
Beifutai	DM6SXRM	Investigative	NA	[13]
BLV-0703	DMBRZ4P	Investigative	NA	[23]
BND-001	DMJI1EA	Investigative	NA	[24]
CIGB-845	DMG2X6U	Investigative	NA	[13]
Conjugated stigmines	DMI1298	Investigative	NA	[13]
CRAM 1-2	DMKVZB6	Investigative	NA	[13]
CXB-029	DMAPRDE	Investigative	NA	[25]
ELB-WE-007	DMV9DK7	Investigative	NA	[13]
IMD-026259	DML4YEA	Investigative	NA	[13]
JN-711	DMFU76I	Investigative	NA	[26]
MC-113	DMPTNUQ	Investigative	NA	[27]
MC-116	DMQC9UB	Investigative	NA	[27]
MEDI-77	DM7FP7M	Investigative	NA	[13]
NPS-P156	DMY93RA	Investigative	NA	[13]
NTP-6009	DMK4KMV	Investigative	NA	[13]
PCAP-1	DMXLRBB	Investigative	NA	[13]
PF-3900422	DM7E391	Investigative	NA	[28]
PheTQS	DMWMBP3	Investigative	NA	[26]
Rh-GDNF	DMKV6SP	Investigative	NA	[13]
SAVX-1	DMF8O62	Investigative	NA	[29]
SCH79687	DM5ZEPD	Investigative	Small molecular drug	[30]
SKL-PD	DM4X2GH	Investigative	NA	[31]
SOM-0009	DM043JC	Investigative	NA	[13]
T-9001	DM093FS	Investigative	NA	[13]
TGFTX-3	DMWOFLX	Investigative	NA	[13]
------------------------------------------------------------------------------------


⏷ Show the Full List of 31 Drug(s)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 2 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
APC2	TTSMK36	Strong	Biomarker	[32]
DLL1	TT9CFQD	Strong	Biomarker	[33]
------------------------------------------------------------------------------------

References

1	Dacarbazine FDA Label
2	Dasatinib FDA Label
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2143).
5	Temozolomide FDA Label
6	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5693).
7	ClinicalTrials.gov (NCT02467634) Study of HUCNS-SC Subretinal Transplantation in Subjects With GA of AMD.
8	List of Drugs in Development for Neurodegenerative Diseases: Update October 2011. Neurodegenerative Dis 2012;9:210-283.
9	Clinical pipeline report, company report or official report of Avicena Group Inc.
10	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
11	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
12	Tumor imaging with 2 sigma-receptor ligands, 18F-FE-SA5845 and 11C-SA4503: a feasibility study. J Nucl Med. 2004 Nov;45(11):1939-45.
13	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
14	Clinical pipeline report, company report or official report of Tris Pharma.
15	Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
16	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033401)
17	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006587)
18	Preclinical Pharmacokinetics of Complement C5a Receptor Antagonists PMX53 and PMX205 in Mice. ACS Omega. 2020 Jan 30;5(5):2345-2354.
19	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017722)
20	Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598). J Pharmacol Exp Ther. 1992 Jan;260(1):146-59.
21	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1420).
22	Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects. Curr Pharm Des. 2011;17(25):2603-12.
23	Microtubules (tau) as an emerging therapeutic target: NAP (davunetide). Curr Pharm Des. 2011;17(31):3413-7.
24	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 320).
25	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 56).
26	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 468).
27	Antitussives and substance abuse. Subst Abuse Rehabil. 2013 Nov 6;4:75-82.
28	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 264).
29	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 594).
30	The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov. 2005 Feb;4(2):107-20.
31	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2490).
32	Directional neuronal migration is impaired in mice lacking adenomatous polyposis coli 2. J Neurosci. 2012 May 9;32(19):6468-84. doi: 10.1523/JNEUROSCI.0590-12.2012.
33	Haploinsufficiency of the Notch Ligand DLL1 Causes Variable Neurodevelopmental Disorders. Am J Hum Genet. 2019 Sep 5;105(3):631-639. doi: 10.1016/j.ajhg.2019.07.002. Epub 2019 Jul 25.